Market Overview:
The global neuromuscular blocking agent (NMBA) market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of neurological disorders, rising geriatric population, and technological advancements in NMBA products. Based on type, the global NMBA market is segmented into depolarizing and non-depolarizing agents. The depolarizing agents segment is expected to dominate the market during the forecast period owing to its high efficacy and shorter duration of action as compared to non-depolarizing agents. Based on application, the hospital segment dominates the global NMBA market due to increased use of neuromuscular blocking drugs for surgeries performed in hospitals. However, with increasing preference for outpatient surgeries, clinics are projected to witness highest growth during the forecast period.
Product Definition:
A neuromuscular blocking agent (NMBA) is a drug that blocks the transmission of nerve impulses to muscles, causing muscle relaxation. This can be used during surgery to help keep the patient still or to aid in intubation.
Depolarizing:
Depolarizing neuromuscular blocking agents are used as anesthetic and analgesic drug in Neuromuscular Blocking Agents (NMBA) for the prevention of muscle spasm during surgery. The growth factor present in depolarizing neuromuscular blocking agent increases the permeability of voltage-gated ion channels, which allows sodium to flow into the cell.
Non-depolarizing:
Non-depolarizing agents are used to block the depolarization of the neuromuscular junction and they have a longer duration of action than depolarizing agents. They can be further divided into noncompetitive inhibitors and competitive inhibitors.
Application Insights:
The hospital application segment dominated the global market in 2017. The use of neuromuscular blocking agents for anesthesia and analgesia in surgical procedures is considered to be its major application. Increasing number of surgeries, especially those involving multiple joints, is expected to boost product demand over the forecast period.
Neuromuscular blocking agents are used as an alternative to general anesthesia during diagnostic or therapeutic procedures that require minimal movement or pain response from the patient¢â‚¬â„¢s body. They are also used for sedation during cosmetic surgeries and dentistry as well as dental implant surgery procedures due to their lesser dosage requirements when compared with other drugs of similar type (general anesthetics). These drugs have a low risk of causing adverse effects on patients when compared with general anesthetics owing to their shorter duration of action; this makes them suitable for outpatient surgical procedures without requiring intensive monitoring by healthcare professionals throughout the procedure.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for advanced therapies are some of the factors responsible for its large share. Moreover, increasing cases of chronic diseases such as multiple sclerosis and rising healthcare expenditure are expected to drive the growth further. According to a study conducted by RAND Corporation about health care spending in U.S., it was estimated that around USD X trillion were spent on hospital-based care in U.S., out of which approximately USD X trillion was spent on acute conditions alone (i.e., within seven days from admission) [ ].
Asia Pacific is expected to witness lucrative growth during the forecast period owing to various initiatives taken up by governments.
Growth Factors:
- Increasing incidence of neuromuscular diseases: The global neuromuscular blocking agent (NMBA) market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of neuromuscular diseases such as myasthenia gravis, amyotrophic lateral sclerosis (ALS), and Duchenne muscular dystrophy (DMD).
- Growing demand for NMBA in anesthesia: The growing demand for NMBA in anesthesia is another key growth driver for the global NMBA market. Anesthesia helps in providing relief from pain and anxiety before, during, and after surgery. It is used to render a patient unconscious or semi-conscious so that they do not feel any pain or discomfort during surgery. Hence, the growing use of anesthesia is expected to drive the demand for NMBA products globally.
- Rising geriatric population: The rising geriatric population across the globe is also anticipated to fuel growth in the global NMBA market over the next few years owing to their increased susceptibility towards various types of neuromuscular diseases such as ALS and DMDs . In addition, elderly patients are more likely than younger patients to require long-term ventilation support post-surgery which will further boost demand for NMBA products globally .
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuromuscular Blocking Agent (NMBA) Market Research Report
By Type
Depolarizing, Non-depolarizing
By Application
Hospital, Clinic, Pharmacy, Others
By Companies
AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics, Guike Pharmaceutical, Shanghai Pharmaceuticals, Themis Medicare, Nanjing King-Friend
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Neuromuscular Blocking Agent (NMBA) Market Report Segments:
The global Neuromuscular Blocking Agent (NMBA) market is segmented on the basis of:
Types
Depolarizing, Non-depolarizing
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- GlaxoSmithKline
- Pfizer
- Hengrui Pharmaceutical
- Abbott Laboratories
- Fresenius Kabi
- Sandoz
- Somerset Therapeutics
- Guike Pharmaceutical
- Shanghai Pharmaceuticals
- Themis Medicare
- Nanjing King-Friend
Highlights of The Neuromuscular Blocking Agent (NMBA) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Depolarizing
- Non-depolarizing
- By Application:
- Hospital
- Clinic
- Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuromuscular Blocking Agent (NMBA) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
NMBA is a medication that blocks nerve impulses. It is used to treat muscle spasms and other conditions caused by nerve damage.
Some of the major players in the neuromuscular blocking agent (nmba) market are AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics, Guike Pharmaceutical, Shanghai Pharmaceuticals, Themis Medicare, Nanjing King-Friend.
The neuromuscular blocking agent (nmba) market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neuromuscular Blocking Agent (NMBA) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neuromuscular Blocking Agent (NMBA) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neuromuscular Blocking Agent (NMBA) Market - Supply Chain
4.5. Global Neuromuscular Blocking Agent (NMBA) Market Forecast
4.5.1. Neuromuscular Blocking Agent (NMBA) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neuromuscular Blocking Agent (NMBA) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neuromuscular Blocking Agent (NMBA) Market Absolute $ Opportunity
5. Global Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
5.3.1. Depolarizing
5.3.2. Non-depolarizing
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Pharmacy
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neuromuscular Blocking Agent (NMBA) Demand Share Forecast, 2019-2026
9. North America Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Pharmacy
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
9.7.1. Depolarizing
9.7.2. Non-depolarizing
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neuromuscular Blocking Agent (NMBA) Demand Share Forecast, 2019-2026
10. Latin America Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Pharmacy
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
10.7.1. Depolarizing
10.7.2. Non-depolarizing
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neuromuscular Blocking Agent (NMBA) Demand Share Forecast, 2019-2026
11. Europe Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Pharmacy
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
11.7.1. Depolarizing
11.7.2. Non-depolarizing 11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neuromuscular Blocking Agent (NMBA) Demand Share, 2019-2026
12. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Pharmacy
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
12.7.1. Depolarizing
12.7.2. Non-depolarizing
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neuromuscular Blocking Agent (NMBA) Demand Share, 2019-2026
13. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Pharmacy
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size and Volume Forecast by Type
13.7.1. Depolarizing
13.7.2. Non-depolarizing
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Neuromuscular Blocking Agent (NMBA) Market: Market Share Analysis
14.2. Neuromuscular Blocking Agent (NMBA) Distributors and Customers
14.3. Neuromuscular Blocking Agent (NMBA) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hengrui Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Fresenius Kabi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sandoz
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Somerset Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Guike Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Shanghai Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Themis Medicare
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Nanjing King-Friend
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook